Literature DB >> 6379510

Chemotherapy of malignant gliomas.

Y Ushio, T Hayakawa, H Hasegawa, K Yamada, N Arita.   

Abstract

Chemotherapy of malignant glioma has been discussed in relation to recent advances in experimental and clinical studies. It is now obvious that chemotherapy is of increasing importance in the multidisciplinary treatment of malignant gliomas. Survival time of patients was prolonged by intensive and prolonged chemotherapy and by second treatment upon tumour recurrence. Further progress of chemotherapy will be gained by the progressive accumulation of all experiences, however small, in all the varied routes of approach.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6379510     DOI： 10.1007/bf01743285

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN： 0344-5607            Impact factor:   3.042


  49 in total

1.  Proceedings: 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms.

Authors:  B D Sklansky; R S Mann-Kaplan; A F Reynolds; M L Rosenblum; M D Walker
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

2.  Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trail.

Authors:  P Pouillart; G Mathe; T H Thy; J Lheritier; M Poisson; P Huguenin; H Gauthier; P Morin; R Parrot
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860

3.  High-dose methotrexate with citrovorum factor rescue for the treatment of central nervous system tumors in children.

Authors:  G Rosen; F Ghavimi; A Nirenberg; C Mosende; B M Mehta
Journal:  Cancer Treat Rep       Date:  1977-07

4.  Treatment of adult malignant gliomas.

Authors:  P Pouillart; T Palangie; M Poisson; A Buge; P Huguenin; P Morin; H Gautier
Journal:  Recent Results Cancer Res       Date:  1978

5.  BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.

Authors:  V A Levin; D C Crafts; C B Wilson; M J Schultz; E B Boldrey; K J Enot; T L Pischer; M Seager; R M Elashoff
Journal:  Cancer Treat Rep       Date:  1976-03

6.  Permeability characteristics of brain adjacent to tumors in rats.

Authors:  V A Levin; M Freeman-Dove; H D Landahl
Journal:  Arch Neurol       Date:  1975-12

7.  High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme.

Authors:  F H Hochberg; L M Parker; T Takvorian; G P Canellos; N T Zervas
Journal:  J Neurosurg       Date:  1981-04       Impact factor: 5.115

8.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

9.  Intra-arterial BCNU therapy in the treatment of metastatic brain tumor from lung carcinoma: a preliminary report.

Authors:  K Yamada; A M Bremer; C R West; J Ghoorah; H C Park; H Takita
Journal:  Cancer       Date:  1979-12       Impact factor: 6.860

10.  Cisplatin therapy in recurrent childhood brain tumors.

Authors:  A B Khan; B J D'Souza; M D Wharam; L A Champion; L F Sinks; S Y Woo; D C McCullough; B G Leventhal
Journal:  Cancer Treat Rep       Date:  1982-12
View more
  8 in total

1.  Dose-intensive, time-compressed procarbazine, CCNU, vincristine (PCV) with peripheral blood stem cell support and concurrent radiation in patients with newly diagnosed high-grade gliomas.

Authors:  R I Jakacki; J Siffert; C Jamison; L Velasquez; J C Allen
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

2.  ACNU, MTX and 5-FU penetration of rat brain tissue and tumors.

Authors:  T Y Huang; N Arita; T Hayakawa; Y Ushio
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

3.  Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens.

Authors:  Raymond I Haroun; Richard E Clatterbuck; M Christopher Gibbons; Peter C Burger; Ricardo Parker; John P Fruehauf; Henry Brem
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

4.  Pharmacokinetics of intrathecal 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride in rats.

Authors:  T Y Huang; N Arita; Y Ushio; T Hayakawa; K Yamada
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Radiation therapy combined with radiosensitizing agents for cerebral glioblastoma in adults.

Authors:  M Matsutani; O Nakamura; M Nakamura; T Nagashima; A Asai; T Fujimaki; H Tanaka; K Ueki; Y Tanaka
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.

Authors:  P Paoletti; G Butti; R Knerich; P Gaetani; R Assietti
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

7.  The effects of local and systemic interferon beta (Fiblaferon) on supratentorial malignant cerebral glioma--a phase II study.

Authors:  K R von Wild; T H Knocke
Journal:  Neurosurg Rev       Date:  1991       Impact factor: 3.042

8.  Intrathecal ACNU--a new therapeutic approach against malignant leptomeningeal tumors.

Authors:  N Arita; Y Ushio; T Hayakawa; M Nagatani; T Y Huang; S Izumoto; H Mogami
Journal:  J Neurooncol       Date:  1988-11       Impact factor: 4.130
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.